Effects of avocado on blood sugar and hunger signals after breakfast
Acute Avocado Consumption on Postprandial Glycemic and Appetite/Satiety Responses
This study is testing if adding avocado to breakfast can help healthy adults control their blood sugar and feel less hungry afterward.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Sponsor | University of Vermont Medical Center Academic / other |
| Locations | 1 site (Burlington, Vermont) |
| Trial ID | NCT06818032 on ClinicalTrials.gov |
What this trial studies
This study investigates how adding avocado to a breakfast meal influences blood sugar control and hunger signals in healthy adults. Participants will consume three different breakfast meals over three test periods, each separated by a week. The meals include variations with and without avocado, as well as a control meal enriched with fat and fiber to mimic avocado's effects. Blood samples will be taken multiple times over four hours after breakfast to assess the impact on glucose and insulin levels.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 21 to 65 with a BMI between 18.5 and 34.9.
Not a fit: Patients with prediabetes, diabetes, or other significant metabolic or chronic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into dietary strategies for better blood sugar management and appetite control.
How similar studies have performed: While there have been studies on the effects of dietary fats on blood sugar, this specific approach with avocado is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Biological sex males or females * Age 21 to 65 years * BMI between 18.5 and 34.9 kg/m2 Exclusion Criteria: * Actively pregnant or lactating women * Diagnosis of prediabetes or diabetes (fasting glucose \>100 mg/dL) * Current diagnosis of uncontrolled hypertension (systolic BP: \>160 mmHg, diastolic BP: \>95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month * Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol \>200 mg/dL, fasting triglycerides \>200 mg/dL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month * Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus) * History of bariatric or certain other surgeries related to weight control * Any medication used to lower blood glucose/antidiabetic medications \[including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors\] as well as medications affecting weight, appetite/hunger or gut motility. * Smoking or use of other tobacco products (during 6 months prior to the start of the study) * Antibiotic use during the intervention or for 3 weeks prior to any treatment period * History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets) * Allergies or adverse reactions to study foods (e.g., gluten intolerance), or food aversions that would interfere with diet adherence * Body weight loss of \>10% within the last 6 months prior to study start * Unable or unwilling to give informed consent or communicate with study staff * Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion) * Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol * Undergoing hormonal therapy of any kind, with the exception of a stable regime for the prior 6 months to study start.
Where this trial is running
Burlington, Vermont
- Clinical Research Center, University of Vermont Medical Center — Burlington, Vermont, United States (Recruiting)
Study contacts
- Principal investigator: Jana Kraft, Ph.D. — University of Vermont
- Study coordinator: Clinical Research Project Manager
- Email: foodstudy@uvm.edu
- Phone: 802-656-8827
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.